// App-Quantinova.ai

P189 : Bimekizumab in patients with psoriatic arthritis with prior inadequate response to TNF inhibitors: improvements of PsARC over 16 weeks in the Phase 3 BE COMPLETE trial

Researchers

Presenter

  • Poonam Sharma

Principal Investigators

  • Deepak R Jadon

  • Dennis McGonagle

  • Barbara Ink

  • Deepak Assudani

  • Vanessa Taieb

  • Laura C Coates

Medical Centers

  • Rheumatology, North West Anglia NHS Foundation Trust, Peterborough, UNITED KINGDOM

  • Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

  • Department of Oncology, University of Cambridge, Cambridge, United Kingdom

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom., National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom

  • Rheumatology, UCB Pharma, Colombes, France

  • Rheumatology, UCB Pharma, Slough, United Kingdom

Locations

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved